Plain-English translation of NCT07335198 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called efimosfersin alfa designed to help with fatty liver disease. Researchers want to understand how safe this medication is, how your body processes it, and how your immune system responds to it. The study includes healthy volunteers from Chinese, Japanese, and European backgrounds to see if the medication works similarly across different populations.
Non-alcoholic fatty liver disease affects millions of people worldwide, and there is a need for new treatment options. This medication is being tested for the first time in Asian populations to ensure it is safe and effective for people of diverse backgrounds before it moves to larger, later-stage studies.
You would visit the study site to receive a single dose of either the medication or a placebo (inactive substance). Researchers will then monitor you closely to check your safety, take blood samples to see how your body processes the medication, and perform heart and other tests. You'll be randomly assigned to receive either the real medication or placebo, and neither you nor the researchers will know which one you receive until the study is complete.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
New Zealand